CCR2 and neoplasm: However, contribution of MDSCs on acquired resistance to anti-VEGF treatment should not be ignored, as recent reports suggest that some populations of MDSCs (CCR2+ or CD11chigh/ CD14−/ CD123−) have a potential to differentiate to fibrocytes and encourage tumour progression46, 62.